Afelimomab

International Journal of Clinical Practice

Volumn 54, Issue 3, 2000, Pages 190-193

  Vincent, J L ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFELIMOMAB; CB 00006; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERSEPT; MAK 195F; NORASEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CROHN DISEASE; DRUG TOLERANCE; HUMAN; INFLAMMATION; META ANALYSIS; MORBIDITY; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK;

CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034048356     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Spooner CE, Markowitz NP, Saravolatz LD. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopath 1992; 62: S11-S17.
2. Maini RN, Elliott MJ, Brennan FM et al. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995; 101: 207-212.
3. Armstrong AM, Gardiner KR, Kirk SJ et al. Tumour necrosis factor and inflammatory bowel disease. Br J Surg 1997; 84: 1051-1058.
4. Raine CS. Multiple sclerosis: TNF revisited, with promise. Nat Med 1995; 1: 211-214.
5. Ksontini R, MacKay SLD, Moldawer LL. Revisiting the role of tumor necrosis factor a and the response to surgical injury and inflammation. Arch Surg 1 998; 133: 558-567.
6. Han J, Huez G, Beutler B. Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions. J Immunol 1991; 146: 1843-1848.
7. Gerain J, Lienard D, Pampallona S et al. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997; 9: 1034-1042.
8. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853-6861.
9. Echtenacher B, Falk W, Mannel DN et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-3766.
10. Bagby GJ, Plessala KJ, Wilson LA et al. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83-88.
11. Van der Poll T, Keogh CV, Buurman WA et al. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155: 603-608.
12. Waage A, Espevik T, Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986; 24: 739-743.
13. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355-357.
14. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-778.
15. Pinsky MR, Vincent JL, Deviere J. Serum cytokine levels in human septic shock: Relation to multiple-systems organ failure and mortality. Chest 1993; 103: 565-575.
16. Damas P, Reuter A, Gysen P et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-979.
17. Debets JM, Kampmeijer R, Van der Linden MP et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-494.
18. Offner F, Philippe J, Vogelaers DP et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116: 100-105.
19. Borrelli E, Roux Lombard P, Grau GE et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996; 24: 392-397.
20. Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486.
21. Rogy MA, Coyle SM, Oldenburg HS et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994; 178: 132-138.
22. Van Deuren M, Van der Ven-Jongekrijk J, Demacker PN et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994; 169: 157-161.
23. Tracey KJ, Wei H, Manogue KR et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988; 167: 1211-1214.
24. Turner CR, Esser KM, Wheeldon EB et al. Cardiovascular and pulmonary effects of human recombinant tumor necrosis factor in the conscious rat. Circ Shock 1989; 28: 369-384.
25. Schirmer JW, Schirmer JM, Fry DE. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 1989; 124: 445-448.
26. Van der Poll T, Bueller HR, ten Cate H et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1 990; 322: 1622-1626.
27. Van der Poll T, Romjin J, Endert E et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991; 261: E457-E465.
28. Van der Poll T, Levi M, Buller HR et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732.
29. Van Deventer SJ, Hart M, Van der Poll T et al. Endotoxin and tumor necrosis factor alpha induced interleukin-8 release in humans. J Infect Dis 1993; 167: 461-464.
30. Van der Poll T, Jansen J, Levi M et al. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180: 1985-1988.
31. Michie HR, Spriggs DR, Manogue KR et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104: 280-286.
32. Spriggs DR, Sherman ML, Michie H et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80: 1039-1044.
33. Bauer KA, ten Cale H, Barzegar S et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74: 165-172.
34. Opal SM, Cross AS, Kelly NM et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1990; 161: 1148-1152.
35. Fiedler VB, Loof I, Sander E et al. Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab C .lin Med 1992; 120: 574-588.
36. Fekade D, Knox K, Hussein K et al. Prevention of Jarisch-Herxheimer reactions hy treatment with antibodies against tumor necrosis factor-α. N Engl J Med 1996; 335: 311-315.
37. Hinshaw LB, Emerson TEJ, Taylor FBJ et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma 1992; 33: 568-573.
38. Hughes CB, Gaber LW, Mohey el-Din AB et al. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg 1996; 62: 8-13.
39. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-9788.
40. Neurath MF, Fuss I, Pasparakis M et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997; 27: 1743-1750.
41. Exley AR, Cohen J, Buurman WA et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275-1277.
42. Vincent JL, Bakker J, Marecaux G et al. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 1992; 101: 810-815.
43. Fisher CJ, Opal SM, Dhainaut JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318-327.
44. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 934-941.
45. Cohen J, Carlet J, INTERSEPT Study Group. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24: 1431-1440.
46. Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-933.
47. Moller A, Emling F, Blohm D et al. Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application. Cytokine 1990; 2: 162-169.
48. Boekstegers P, Weidenhofer S, Zell R et al. Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1994; 1: 237-245.
49. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 1996; 24: 733-742.
50. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5: 119-133.
51. Suter PM, Suter S, Girardin E et al. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022.
52. Holzheimer RG, Schein M, Wittmann DH. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondaryperitonitis. Arch Surg 1995; 130: 1314-1319.
53. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362.
54. Reinhart K, RAMSES Study Group. Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The RAMSES study. Crit Care 1998; 2: P18 (Abstract).
55. Fisher CJ, Jr., Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
56. Abraham E, Glauser MP, Butler T et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277: 1531-1538.
57. Maini RN, St.Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-1936.
58. Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-1035.
59. Vincent JL. Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351: 922-923.